Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2

[1]  O. Volpert,et al.  NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. , 2010, Blood.

[2]  A. Papavassiliou,et al.  Atypical induction of the unfolded protein response by mifepristone , 2010, Endocrine.

[3]  Yung-Hyun Choi,et al.  The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. , 2010, Chemico-biological interactions.

[4]  Junhui Huang,et al.  [Reversal effect of mifepristone on adriamycin resistance in human breast cancer cell line MCF-7/ADM in vitro and in vivo]. , 2010, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[5]  P. Garcia-Lopez,et al.  Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. , 2009, Oncology reports.

[6]  Tae-Jin Lee,et al.  Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. , 2009, International journal of oncology.

[7]  J. Eriksson,et al.  PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability , 2009, Cell Death and Differentiation.

[8]  Baolin Zhang,et al.  TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5 , 2008, Molecular Cancer Research.

[9]  A. Safa,et al.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. , 2008, Current cancer drug targets.

[10]  H. Otu,et al.  c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. , 2007, Cancer research.

[11]  S. Conzen,et al.  Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. , 2006, European journal of cancer.

[12]  G. Feldmann,et al.  Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. , 2006, Oncology reports.

[13]  Qing Gao,et al.  [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro]. , 2006, Zhonghua wai ke za zhi [Chinese journal of surgery].

[14]  T. Shiraishi,et al.  Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. , 2005, Cancer research.

[15]  H. Yamaguchi,et al.  CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[16]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[17]  Amnon Zisman,et al.  Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL‐mediated apoptosis of prostate cancer cells: Role of XIAP in resistance , 2002, The Prostate.

[18]  B. Hoel,et al.  Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of c-FLIP Expression , 2002, Cancer biology & therapy.

[19]  Mansoor M Ahmed,et al.  Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3 , 2002, Cancer biology & therapy.

[20]  M. Eid,et al.  Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). , 2002, Molecular cancer therapeutics.

[21]  A. López-Rivas,et al.  The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels , 2001, Oncogene.

[22]  J. Tschopp,et al.  Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells , 2001, Oncogene.

[23]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[24]  P. Krammer,et al.  Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. , 2000, Cancer research.

[25]  A. Vaughan,et al.  RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. , 2000, Gynecologic oncology.

[26]  M. Plescia,et al.  Mifepristone (RU 486): current knowledge and future prospects. , 1998, Archives of family medicine.

[27]  S. London,et al.  Mifepristone (RU486): a review. , 1997, Fertility and sterility.

[28]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[29]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[30]  A. Robbins,et al.  Mifepristone: clinical pharmacology. , 1996, Clinical obstetrics and gynecology.

[31]  O. Sartor,et al.  Mifepristone: antineoplastic studies. , 1996, Clinical obstetrics and gynecology.

[32]  F. Rose,et al.  Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. , 1996, Oncogene.

[33]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[34]  O. Fardel,et al.  The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P‐glycoprotein function , 1994, FEBS letters.

[35]  G. Vielvoye,et al.  Successful mifepristone treatment of recurrent, inoperable meningioma , 1990, The Lancet.

[36]  D. W. Beck,et al.  Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. , 1987, Journal of neurosurgery.

[37]  D. Philibert,et al.  RU 38486: a potent antiglucocorticoid in vitro and in vivo. , 1985, Journal of steroid biochemistry.

[38]  D. Chalbos,et al.  RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. , 1985, The Journal of clinical endocrinology and metabolism.

[39]  E. Baulieu,et al.  Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor. , 1983, Experimental cell research.

[40]  G. Teutsch,et al.  [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. , 1982, Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie.

[41]  T. Kataoka.  The caspase-8 modulator c-FLIP. , 2005, Critical reviews in immunology.

[42]  R. Bonelli.  [Mifepristone (RU 486)]. , 1992, Diskussionsforum medizinische Ethik.